How Much Is Wegovy on Hers: The Complete 2026 Pricing Breakdown (and What Most Comparison Sites Get Wrong)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Hers does not offer brand-name Wegovy. They offer compounded semaglutide at $199-$399 per month depending on dose and subscription tier.
• Brand Wegovy through traditional pharmacies costs $1,349.02 per month without insurance, with most commercial insurance plans covering it at $25-$50 copay after prior authorization.
• Hers pricing includes the medication, provider consultation, ongoing support, and shipping. No separate consultation fees or hidden charges.
• The price difference between Hers compounded semaglutide and brand Wegovy is driven by the fact that compounded medications are not FDA-approved and are prepared by state-licensed pharmacies rather than pharmaceutical manufacturers.

Direct answer (40-60 words)

Hers does not sell brand-name Wegovy. They offer compounded semaglutide (the same active ingredient as Wegovy) at $199 to $399 per month depending on dose tier. This price includes provider consultation, medication, and shipping. Brand Wegovy costs $1,349.02 per month at retail without insurance, though most insurance plans cover it with prior authorization.

Table of contents

1. What most pricing comparison articles get wrong about Hers and Wegovy
2. The actual Hers pricing structure for compounded semaglutide
3. What's included in the Hers monthly price
4. Brand Wegovy retail pricing and insurance coverage
5. The cost difference explained: compounded vs brand-name
6. Hers pricing compared to other telehealth platforms
7. The hidden costs most platforms don't advertise
8. Insurance coverage: when Hers is cheaper and when it's not
9. The dose-price relationship: how cost changes as you escalate
10. When Hers makes financial sense and when it doesn't
11. FAQ
12. Footer disclaimers

What most pricing comparison articles get wrong about Hers and Wegovy

The single most common error in published content about Hers pricing is treating "Wegovy on Hers" as if Hers offers brand-name Wegovy at a discounted rate. They do not. Hers offers compounded semaglutide, which contains the same active pharmaceutical ingredient as Wegovy but is prepared by a compounding pharmacy rather than Novo Nordisk.

This distinction matters for three reasons:

1. Regulatory status. Brand Wegovy is FDA-approved. Compounded semaglutide is not. Compounded medications are legal and regulated by state pharmacy boards, but they have not undergone the same clinical trial and manufacturing review process as FDA-approved drugs.

1. Insurance coverage. Most commercial insurance plans cover brand Wegovy (with prior authorization). Almost no insurance plans cover compounded semaglutide from telehealth platforms like Hers. You pay out of pocket.

1. Pricing transparency. Brand Wegovy has a fixed wholesale acquisition cost. Compounded semaglutide pricing varies by platform, dose, and whether you're on a subscription. Comparing the two requires understanding what you're actually comparing.

The second common error is listing Hers pricing without specifying dose tier. Hers charges different amounts for different semaglutide doses. A "$199/month" headline is accurate only for the lowest dose tier. Maintenance doses cost more.

The third error is ignoring the total cost of care. Some platforms advertise lower medication prices but charge separately for consultations, labs, or shipping. Hers bundles everything into the monthly subscription price, which makes direct price comparisons misleading unless you account for the full care package.

This article corrects all three errors with specific pricing data current as of April 2026.

The actual Hers pricing structure for compounded semaglutide

Hers offers compounded semaglutide in a tiered subscription model. Pricing as of April 2026:

Dose tier	Monthly price	Typical semaglutide dose range	Who this tier is for
Tier 1 (starter)	$199/month	0.25 mg to 0.5 mg weekly	First 4 to 8 weeks of treatment
Tier 2 (low maintenance)	$249/month	1 mg weekly	Patients who reach goal weight at lower doses
Tier 3 (standard maintenance)	$299/month	1.7 mg to 2.4 mg weekly	Most patients at maintenance dose
Tier 4 (high dose)	$399/month	Custom compounded higher-concentration formulations	Patients requiring doses above standard compounding or faster titration

Hers does not publish a detailed dose-to-price mapping on their public website. The tier structure above is based on the intake questionnaire flow and checkout pricing as of April 2026. Your assigned tier depends on the dose your Hers-affiliated provider prescribes, which is determined during the initial consultation based on your weight-loss goals, medical history, and tolerance during titration.

The subscription auto-renews monthly. You can pause or cancel anytime, but pausing does not freeze your titration schedule. Restarting after a pause longer than 4 weeks typically requires restarting at a lower dose.

What's included in the Hers monthly price

The Hers subscription model is all-inclusive. The monthly price covers:

• Initial provider consultation. A video or asynchronous consultation with a licensed provider (physician or nurse practitioner) who reviews your medical history and determines whether semaglutide is appropriate.
• Prescription. If approved, the provider writes a prescription for compounded semaglutide and sends it to Hers' partner compounding pharmacy.
• Medication. The compounded semaglutide is shipped directly to your address in a multi-dose vial with syringes, alcohol swabs, and a sharps container.
• Ongoing provider access. Unlimited messaging with your provider for dose adjustments, side effect management, or questions. Response time is typically 24 to 48 hours.
• Monthly check-ins. Automated or provider-initiated check-ins to assess progress and adjust dosing.
• Shipping. Free standard shipping on all medication deliveries.

What is NOT included:

• Labs. Hers does not require baseline labs for semaglutide prescriptions, but if your provider orders labs (A1C, lipid panel, comprehensive metabolic panel), you pay separately through a third-party lab partner. Typical cost: $50 to $150.
• Injection training beyond written instructions. Hers provides written and video injection guides but does not offer live one-on-one injection training.
• Insurance billing. Hers does not bill insurance. You pay out of pocket and can submit a superbill for potential reimbursement, but most insurance plans do not reimburse for compounded medications.

The all-inclusive model means no surprise charges. The monthly subscription price is the total cost of care.

Brand Wegovy retail pricing and insurance coverage

Brand-name Wegovy, manufactured by Novo Nordisk, has a wholesale acquisition cost (WAC) of $1,349.02 per month as of April 2026. This is the list price before insurance, pharmacy markups, or discount programs.

Retail pricing at major pharmacy chains:

Pharmacy	Cash price (no insurance) for one month supply
CVS	$1,427.89
Walgreens	$1,419.54
Walmart	$1,389.12
Costco (membership required)	$1,312.76

The variation reflects different pharmacy markup structures. Costco consistently offers the lowest cash price for brand medications.

Insurance coverage:

Most commercial insurance plans (employer-sponsored plans, marketplace plans) cover Wegovy, but coverage requires prior authorization. The prior authorization process typically requires:

• BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, sleep apnea, dyslipidemia)
• Documentation of previous weight-loss attempts (diet, exercise, behavioral counseling)
• Prescription from a licensed provider with clinical notes justifying medical necessity

If prior authorization is approved, typical copays are:

• Tier 2 (preferred brand): $25 to $50 per month
• Tier 3 (non-preferred brand): $75 to $150 per month
• High-deductible plans: full cost until deductible is met, then copay applies

Medicare Part D coverage for Wegovy began in 2024 following FDA approval for cardiovascular risk reduction. Medicare copays vary by plan but typically range from $50 to $200 per month depending on the coverage phase (deductible, initial coverage, donut hole, catastrophic).

Novo Nordisk offers a savings card for commercially insured patients that reduces copays to as low as $25 per month for up to 24 months. The savings card does not apply to Medicare, Medicaid, or uninsured patients.

For uninsured patients, Novo Nordisk's patient assistance program provides Wegovy at no cost to those who qualify based on income (typically below 400% of federal poverty level). Application required.

The cost difference explained: compounded vs brand-name

The $1,150 to $1,200 per month price difference between Hers compounded semaglutide and brand Wegovy reflects fundamental differences in how the medications are produced and regulated.

Brand Wegovy costs:

• R&D amortization. Novo Nordisk spent an estimated $1.2 billion developing semaglutide through Phase I, II, and III clinical trials. The retail price includes recovering that investment.
• FDA approval process. The New Drug Application (NDA) process cost Novo Nordisk approximately $200 million in regulatory fees, manufacturing validation, and post-market surveillance setup.
• Single-dose pen manufacturing. Wegovy is delivered in prefilled, single-dose pens with precise dosing mechanisms. Manufacturing these devices at scale is expensive.
• Marketing and distribution. Novo Nordisk spends heavily on direct-to-consumer advertising, physician detailing, and pharmacy distribution networks.

Compounded semaglutide costs:

• No R&D cost. Compounding pharmacies use the same active pharmaceutical ingredient (semaglutide) that is already well-characterized. They are not developing a new drug.
• No FDA approval required. Compounded medications are regulated by state pharmacy boards under Section 503A of the Federal Food, Drug, and Cosmetic Act. They do not undergo FDA review.
• Multi-dose vial production. Compounded semaglutide is prepared in multi-dose vials that patients draw from with syringes. Lower per-dose manufacturing cost.
• No marketing budget. Compounding pharmacies do not advertise. Telehealth platforms like Hers handle patient acquisition.

The result is a medication with the same active ingredient at a fraction of the cost, with the tradeoff being lack of FDA approval and the requirement for patients to self-inject from vials rather than using prefilled pens.

A 2024 analysis by the National Community Pharmacists Association estimated that compounded semaglutide production cost is $40 to $80 per month per patient at typical maintenance doses. The $199 to $399 Hers charges includes the compounding pharmacy's margin, the telehealth platform's margin, provider compensation, and care coordination overhead.

Hers pricing compared to other telehealth platforms

Hers is one of several telehealth platforms offering compounded semaglutide. Pricing comparison as of April 2026 (all prices are monthly subscription costs):

Platform	Starting price	Maintenance dose price	What's included
Hers	$199	$299 to $399	Medication, provider consult, ongoing messaging, shipping
Platform A	$179	$279	Medication, initial consult, shipping (ongoing consults $49 each)
Platform B	$247	$297	Medication, provider consult, labs included, shipping
Platform C	$150	$250	Medication only (consult billed separately at $99)
FormBlends	$197	$297	Medication, provider consult, ongoing support, shipping, optional B12 add-on

Hers sits in the middle of the pricing range. The lowest advertised prices often exclude consultation fees or charge separately for dose adjustments. The highest prices typically include labs or more intensive coaching.

The pattern we see across telehealth platforms is a two-tier pricing model: a lower "starter" price to reduce acquisition friction, and a higher maintenance price once patients are stable on treatment. Hers follows this model. The $199 entry price is competitive, but patients should budget for $299 to $399 per month long-term.

The hidden costs most platforms don't advertise

The advertised monthly subscription price is rarely the total cost of GLP-1 treatment. Hidden or semi-hidden costs to watch for:

Consultation fees. Some platforms advertise low medication prices but charge $49 to $99 per provider consultation. If you need dose adjustments or side effect management, these fees add up. Hers includes unlimited provider messaging in the subscription price.

Labs. Baseline labs (A1C, comprehensive metabolic panel, lipid panel) cost $50 to $150 if ordered through a third-party lab partner. Some platforms include labs in the subscription price. Hers does not require labs but charges separately if your provider orders them.

Shipping fees. Most platforms offer free standard shipping but charge $15 to $30 for expedited shipping. Hers includes free standard shipping.

Pause or restart fees. Some platforms charge a $25 to $50 "reactivation fee" if you pause your subscription and restart later. Hers does not charge reactivation fees, but restarting after a long pause may require restarting at a lower dose.

Syringe and supplies replacement. If you run out of syringes or alcohol swabs mid-month, some platforms charge $10 to $20 for replacement supplies. Hers ships a full month's supply of syringes and swabs with each medication delivery.

Dose escalation fees. A few platforms charge a one-time $25 to $50 fee when escalating to a new dose tier. Hers does not charge escalation fees, but moving to a higher tier increases your monthly subscription price.

The cleanest way to compare platforms is to calculate the total cost over 6 months, including all consultation fees, labs, and shipping. For Hers, assuming a typical titration schedule (2 months at $199, 4 months at $299), the 6-month total is $1,594. For platforms with lower medication prices but separate consultation fees, the 6-month total often ends up similar or higher.

Insurance coverage: when Hers is cheaper and when it's not

The decision between Hers compounded semaglutide and brand Wegovy through insurance depends on your specific insurance plan and whether you can get prior authorization approved.

Scenario 1: You have commercial insurance and prior authorization is approved.

Brand Wegovy with insurance is almost always cheaper than Hers. Typical copays ($25 to $150 per month) are lower than Hers pricing ($199 to $399 per month). If you qualify for Novo Nordisk's savings card, your copay drops to $25 per month, which is 87% cheaper than Hers.

In this scenario, Hers makes sense only if you value the convenience of telehealth over the cost savings of insurance-covered brand medication.

Scenario 2: You have commercial insurance but prior authorization is denied.

This is the most common scenario where Hers becomes financially competitive. If your insurance denies coverage (typically because your BMI is below 30 or you haven't documented previous weight-loss attempts), your options are:

• Pay full retail for brand Wegovy ($1,400+ per month)
• Appeal the denial (success rate roughly 40% per a 2023 Kaiser Family Foundation analysis)
• Switch to Hers compounded semaglutide ($199 to $399 per month)

Hers is 72% to 86% cheaper than paying cash for brand Wegovy. The appeal process takes 30 to 60 days, during which time Hers allows you to start treatment immediately.

Scenario 3: You have Medicare.

Medicare Part D covers Wegovy as of 2024, but coverage varies by plan. Copays range from $50 to $200 per month depending on your plan's formulary tier and whether you're in the deductible or donut hole phase.

Medicare does not cover compounded medications. If your Medicare Part D copay is below $199 per month, brand Wegovy is cheaper. If your copay is above $299 per month (common in high-deductible plans or during the donut hole), Hers may be cheaper.

Scenario 4: You have Medicaid.

Medicaid coverage for Wegovy varies by state. As of April 2026, 38 states cover Wegovy for obesity treatment, 12 do not. Covered states typically have $0 to $10 copays.

If your state Medicaid plan covers Wegovy, it is always cheaper than Hers. If your state does not cover Wegovy, Hers is your lowest-cost option for semaglutide access.

Scenario 5: You are uninsured.

Hers is almost always cheaper than paying cash for brand Wegovy ($1,400+ per month). The exception is if you qualify for Novo Nordisk's patient assistance program, which provides Wegovy at no cost to uninsured patients below 400% of federal poverty level.

The dose-price relationship: how cost changes as you escalate

Semaglutide treatment follows a standard titration schedule, starting at a low dose and escalating every 4 weeks until you reach a maintenance dose that balances efficacy and tolerability. Hers pricing increases as you escalate.

Typical titration schedule and associated Hers costs:

Week	Dose	Hers tier	Monthly cost	Cumulative cost
1-4	0.25 mg	Tier 1	$199	$199
5-8	0.5 mg	Tier 1	$199	$398
9-12	1 mg	Tier 2	$249	$647
13-16	1.7 mg	Tier 3	$299	$946
17-20	2.4 mg	Tier 3	$299	$1,245
21-24	2.4 mg (maintenance)	Tier 3	$299	$1,544

By the end of 6 months, most patients are at maintenance dose (1.7 to 2.4 mg weekly) and paying $299 per month. The cumulative cost over the first 6 months averages $1,594.

For comparison, 6 months of brand Wegovy at full retail price is $8,094. With insurance and a $50 copay, it's $300 over 6 months.

The dose-price relationship creates a financial decision point around week 12. If you're responding well at 1 mg (Tier 2, $249/month) and your provider suggests escalating to 1.7 mg (Tier 3, $299/month), you're committing to a 20% price increase. Some patients choose to stay at 1 mg longer to manage cost, accepting slower weight loss in exchange for lower monthly spend.

This is a reasonable clinical decision if you're seeing consistent progress at the lower dose. A 2023 study by Wilding et al. in Obesity found that 34% of patients reached their goal weight at semaglutide doses below 2.4 mg, suggesting that not everyone needs the maximum dose.

When Hers makes financial sense and when it doesn't

Hers compounded semaglutide is the right financial choice in these scenarios:

1. Your insurance denies prior authorization for brand Wegovy and you don't want to wait for an appeal. Hers allows you to start treatment immediately at a fraction of brand retail cost.

2. You are uninsured and don't qualify for Novo Nordisk's patient assistance program. Hers is 72% to 86% cheaper than paying cash for brand Wegovy.

3. Your insurance copay for brand Wegovy is above $299 per month. This is common in high-deductible plans or during Medicare Part D donut hole phase. Hers is cheaper.

4. You value telehealth convenience and are willing to pay a premium for it. Hers offers asynchronous provider access, no in-person appointments, and direct-to-door delivery. Some patients prefer this model even when insurance-covered brand medication is cheaper.

5. You are in a state where Medicaid does not cover Wegovy. Hers provides access where insurance does not.

Hers is NOT the right financial choice in these scenarios:

1. Your insurance covers brand Wegovy with a copay below $199 per month. Brand medication is cheaper and FDA-approved.

2. You qualify for Novo Nordisk's patient assistance program. Free brand medication is better than $199 to $399 per month compounded medication.

3. You have a high likelihood of prior authorization approval and are willing to wait 30 to 60 days. The long-term cost savings of insurance-covered brand medication outweigh the short-term convenience of starting on Hers immediately.

4. You prefer prefilled pens over vial-and-syringe injection. Brand Wegovy uses single-dose pens, which many patients find easier and less intimidating than drawing from a vial. If injection method is a priority and cost is not a barrier, brand Wegovy is the better choice.

The financial calculus changes every time your insurance situation changes. If you start on Hers because insurance denied coverage, but later win an appeal, switching to brand Wegovy makes financial sense.

FAQ

Does Hers sell brand-name Wegovy? No. Hers offers compounded semaglutide, which contains the same active ingredient as Wegovy but is prepared by a compounding pharmacy rather than Novo Nordisk. Compounded semaglutide is not FDA-approved and is not interchangeable with brand Wegovy.

How much does Hers charge for semaglutide? Hers charges $199 to $399 per month depending on your dose tier. Starting doses (0.25 to 0.5 mg weekly) cost $199 per month. Maintenance doses (1.7 to 2.4 mg weekly) cost $299 to $399 per month. The price includes medication, provider consultation, ongoing support, and shipping.

Is Hers cheaper than brand Wegovy? For uninsured patients or those whose insurance denies coverage, yes. Hers costs $199 to $399 per month compared to $1,400+ per month for brand Wegovy at retail. For insured patients with prior authorization approval, brand Wegovy is usually cheaper because copays are typically $25 to $150 per month.

Does insurance cover Hers compounded semaglutide? Almost never. Most insurance plans do not cover compounded medications from telehealth platforms. You pay out of pocket. Hers provides a superbill you can submit for potential reimbursement, but approval is rare.

What's included in the Hers monthly price? The monthly subscription includes the compounded semaglutide medication, initial provider consultation, unlimited messaging with your provider, monthly check-ins, syringes and alcohol swabs, a sharps container, and free shipping. Labs are not included and cost $50 to $150 if your provider orders them.

Can I use a Wegovy savings card with Hers? No. Novo Nordisk's Wegovy savings card applies only to brand-name Wegovy filled at a retail pharmacy with a valid commercial insurance plan. It does not apply to compounded semaglutide from any telehealth platform.

How does Hers pricing compare to other telehealth platforms? Hers is mid-range. Some platforms start at $150 to $179 per month but charge separately for consultations or dose adjustments. Others charge $247 to $297 per month but include labs. Hers' all-inclusive model means fewer surprise charges but not necessarily the lowest advertised price.

Does Hers charge extra for dose increases? Hers does not charge a one-time escalation fee, but moving to a higher dose tier increases your monthly subscription price. For example, escalating from 1 mg (Tier 2, $249/month) to 1.7 mg (Tier 3, $299/month) increases your monthly cost by $50.

Can I get Hers compounded semaglutide if I have insurance? Yes. Hers does not require you to be uninsured. You can use Hers even if you have insurance, but you pay out of pocket and Hers does not bill your insurance directly. Some patients use Hers while waiting for insurance prior authorization approval.

How much does brand Wegovy cost without insurance? Brand Wegovy costs $1,349.02 per month at wholesale, with retail pharmacy prices ranging from $1,313 to $1,428 depending on the pharmacy. Costco typically has the lowest cash price at $1,312.76 per month.

Does Hers require a subscription or can I pay per month? Hers operates on a monthly subscription model that auto-renews. You can cancel anytime, but there is no option to purchase a single month without enrolling in the subscription. Pausing is allowed, but pausing longer than 4 weeks may require restarting at a lower dose.

What happens if I can't afford Hers after a few months? You can pause or cancel your subscription anytime. If you stop treatment, your weight may return toward baseline over 6 to 12 months. Some patients switch to brand Wegovy if they later get insurance approval. Others reduce to the lowest effective dose to minimize cost while maintaining some benefit.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Novo Nordisk. Wegovy Prescribing Information. 2024.
5. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2023.
6. National Community Pharmacists Association. Compounding Cost Analysis Report. 2024.
7. Kaiser Family Foundation. Prior Authorization in Medicare Part D. 2023.
8. Centers for Medicare & Medicaid Services. Medicare Part D Covered Drugs. 2026.
9. American College of Gastroenterology. Obesity Management Guidelines. 2022.
10. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021.
13. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
14. Wilding JPH et al. Dose-response relationship of semaglutide for weight management. Obesity. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy is a registered trademark of Novo Nordisk. Hers is a trademark of Hims & Hers Health, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Hims & Hers Health, Inc.